GlassScriptPhysician profile
Jonathan Yujung Yun
NPI 1275572349
$7,955.20
in general payments reported to CMS, 2019-2025
31 companies · $752 in 2025
The $752 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $1,129 · 2021: $1,410 · 2022: $1,462 · 2023: $889 · 2024: $1,385 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,025.43 | 2021-2024 | Eterna, Proclaim |
| Astrazeneca Pharmaceuticals LP | $1,221.73 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,000.24 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $942.43 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $552.63 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $300.63 | 2019-2022 | |
| Pfizer INC. | $300.17 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $219.52 | 2020-2021 | |
| Glaxosmithkline, LLC. | $174.57 | 2020-2023 | Shingrix |
| Phathom Pharmaceuticals, INC. | $174.21 | 2024 | Voquezna |
| Hologic Sales and Service, LLC | $147.15 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Daiichi Sankyo INC. | $125.00 | 2024 | Injectafer |
| Vanda Pharmaceuticals INC. | $102.98 | 2020 | |
| Amarin Pharma, INC. | $89.30 | 2020 | |
| Mannkind Corporation | $80.88 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $69.92 | 2020-2024 | |
| Edwards Lifesciences Corporation | $46.91 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Corcept Therapeutics | $39.38 | 2019-2021 | |
| Medtronic, INC. | $38.22 | 2024 | Minimed 780g |
| Exact Sciences Corporation | $36.33 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.25 | 2025 | Jardiance |
| Astellas Pharma US INC | $31.70 | 2019 | |
| Ucb, INC. | $31.53 | 2025 | Briviact |
| Eyevance Pharmaceuticals LLC | $24.87 | 2021 | |
| Hikma Pharmaceuticals USA | $24.87 | 2021 | |
| Neotract INC. | $23.82 | 2020 | |
| Nestle Healthcare Nutrition INC. | $23.54 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $21.96 | 2022 | |
| Si-Bone, INC. | $19.13 | 2022 | |
| Electromed, INC. | $17.37 | 2023 | Smartvest |
| Medtronic Minimed, INC. | $16.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Yun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.